Scarica l'app Stockscreener
3.54
6.10%
-0.23
Precedente Chiudi:
$3.77
Aprire:
$3.88
Volume 24 ore:
249.16K
Relative Volume:
0.89
Capitalizzazione di mercato:
$77.23M
Reddito:
-
Utile/perdita netta:
$-57.59M
Rapporto P/E:
-1.3366
EPS:
-2.6486
Flusso di cassa netto:
$-54.27M
1 W Prestazione:
-27.46%
1M Prestazione:
-71.41%
6M Prestazione:
-72.06%
1 anno Prestazione:
-61.06%
Intervallo 1D:
$3.52
$3.88
Intervallo di 1 settimana:
$3.52
$4.98
Portata 52W:
$3.52
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
3.54 | 77.23M | 0 | -57.59M | -54.27M | -2.6486 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Downgrade | Stifel | Buy → Hold |
| 2026-01-28 | Iniziato | B. Riley Securities | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-12 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Australia
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com UK
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com Canada
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks - TipRanks
B.Riley cuts Aardvark Therapeutics stock price target on trial pause - Investing.com India
Aardvark Therapeutics Pauses Phase 3 Trials for ARD-101 in Prader-Willi Syndrome, Reports 2025 Financial Results and Pipeline Updates - Minichart
Aardvark Therapeutics Establishes $150 Million Equity Program - TipRanks
Aardvark Therapeutics (NASDAQ: AARD) launches $150M at-the-market stock program - Stock Titan
Aardvark Therapeutics Launches $150 Million ATM Equity Program With Piper Sandler - TradingView
Aardvark Therapeutics, Inc. – Clinical-Stage Biopharma Advancing TAS2R Small-Molecule Therapies for Obesity and Metabolic Diseases - Minichart
Aardvark Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Aardvark Therapeutics (AARD) registers $400M shelf; $150M ATM included - Stock Titan
Aardvark Therapeutics reports fourth quarter and full year 2025 financial results and provides business updates - marketscreener.com
Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS - TradingView
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Aardvark Therapeutics (AARD) halts ARD-101 PWS Phase 3 to probe cardiac signal - Stock Titan
AARD: Clinical trial pauses and strong cash reserves define the period, with guidance due in Q2 2026 - TradingView
Aardvark Therapeutics (NASDAQ: AARD) halts ARD-101 and ARD-201 trials as 2025 loss widens - Stock Titan
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) EstimateAardvark Therapeutics (NASDAQ:AARD) - Benzinga
Aardvark halts obesity and PWS studies after reversible heart findings - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Breakouts Watch: Can Aardvark Therapeutics Inc expand its profit margins2026 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Investors to Inquire about Securities Investigation - ACCESS Newswire
If You Invested $1,000 in Aardvark Therapeutics (AARD) - Stock Titan
AARD SEC FilingsAardvark Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next - TipRanks
Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors - TipRanks
Aardvark Therapeutics, Inc. (AARD) - MSN
HC Wainwright & Co. downgrades Aardvark Therapeutics (AARD) - MSN
Earnings Recap: Can Aardvark Therapeutics Inc reach all time highs this year - baoquankhu1.vn
AARD stock slumps 54% pre-market – here’s why analysts are not comfortable with the suspension of a key phase 3 trial - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Arcellx and Aardvark Therapeutics Compared - National Today
Analyzing Arcellx (NASDAQ:ACLX) and Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Aug Wrap: Does Aardvark Therapeutics Inc have a competitive edge2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Cresset Asset Management Invests $1.95M in Aardvark Therapeutics - National Today
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
New Highs: Should I trade or invest in Aardvark Therapeutics Inc2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):